摘要
目的评价阿托伐他汀治疗急性缺血性脑卒中的临床疗效和安全性。方法本研究将80例急性缺血性脑卒中患者随机分为试验组(40例)和对照组(40例)。对照组患者在常规治疗基础上给予口服肠溶阿斯匹林片治疗。试验组在对照组治疗基础上,给予口服阿托伐他汀治疗。观察比较治疗后两组患者的临床疗效,血脂水平变化和不良反应发生情况。结果治疗12周后,试验组患者的总有效率为90.0%,显著高于对照组的62.5%(P<0.05)。试验组患者的TG、TC、HDL-C和LDL-C改善均显著优于对照组患者(P<0.05)。试验组不良反应发生率为5.0%,显著低于对照组的17.5%(P<0.05)。结论阿托伐他汀治疗急性缺血性脑卒中疗效显著,且不良反应轻微,值得临床推广应用。
Objective To assess the efficacy and safety of atorvastatin （ATV） for treating acute ischemic stroke （AIS）. Methods A total of 84 AIS subjects were randomly divided into the intervention group and control group,each group 40 cases. The patients in the control group were given aspirin tablet （AST）,while subjects in intervention group were treated with AST and ATV. The outcomes include clinical efficacy,blood lipid levels and adverse events （AEs）. Results After 12-week treatment,the total effective rate was 90. 0% in intervention group,which is much higher than 62. 5% in control group （P〈0. 05）. The improvement of TG,TC,HDL-C and LDL-C in intervention group were much better than those in control group （P〈0. 05）. The AEs rate was 5. 0% in intervention group,which is much lower than 17. 5% in control group （P〈0. 05）. Conclusion Atorvastatin has significant efficacy for treating acute ischemic stroke with few adverse events,thus,it deserves to be applied in clinic.
作者
刘胜武
郭改艳
吴瑞
王柳义
LIU Sheng - wu GUO Gai - yah WU Rui WANG Liu - yi(Department of Neurology, Affiliated Hospital of Yan ＇an University, Yan＇an 716000, China)
出处
《延安大学学报（医学科学版）》
2017年第3期11-13,17,共4页
Journal of Yan'an University:Medical Science Edition
